Prognostic Value of Ventricular Fibrillation Spectral Analysis in Sudden Cardiac Death (AWAKE)

• ClinicalTrials.gov Identifier: NCT03248557
• Recruitment Status: Recruiting
• First Posted: August 14, 2017
• Last Update Posted: February 16, 2021
• Sponsor: Hospital San Carlos, Madrid
• Collaborators: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III; Hospital Universitario La Paz; Hospital General de Ciudad Real; Fundación de Investigación en Red en Enfermedades Cardiovasculares; Hospital General Universitario Gregorio Marañon; Sociedad Española de Cardiología; Fundacion Investigacion Interhospitalaria Cardiovascular
• Information provided by (Responsible Party): David Filgueiras-Rama, Hospital San Carlos, Madrid

Study Description

Brief Summary:

Ventricular fibrillation (VF)-related sudden cardiac death (SCD) is a leading cause of mortality. Patients may survive with neurological damage despite state-of-the-art treatment. Current biological and imaging parameters show significant limitations on early predicting cerebral performance at hospital admission. A spectral-based model was recently suggested to correlate time-dependent VF spectral changes with acute cerebral injury in comatose survivors after cardiac arrest, which opens the possibility to implement early prognostic tools in clinical practice. The AWAKE trial is an investigator-initiated, multicenter, observational trial aiming to validate a spectral-based model to early predict cerebral performance and survival in resuscitated comatose survivors admitted to specialized intensive care units. The primary clinical outcome is favorable neurological performance (FNP) during hospitalization. Patients will be categorized into 4 subsets of NP according to the risk score obtained from the predictive model. The secondary clinical outcomes are survival to hospital discharge, and FNP and survival after 6 months of follow-up. Model-derived categorization will be compared with clinical outcomes to assess model sensitivity, specificity and accuracy. Eligible patients will be included prospectively and retrospectively, using an electronic Case Report Form to enter data from medical records and in-person interviews. Patients will be divided into: study group (predictive data required) including comatose (Glasgow Coma Scale -GCS- ≤8) survivors undergoing temperature control after return of spontaneous circulation (RoSC), and control group including patients who regain consciousness (GCS=15) after RoSC. VF tracings prior to the first DC shock will be digitized and analyzed to derive spectral data and risk scores.

Condition or disease	Intervention/treatment
Sudden Cardiac Death; Ventricular Fibrillation; Reperfusion Injury	Diagnostic Test: Spectral analysis of ventricular fibrillation tracings

Detailed Description:

Trial design:

The AWAKE trial is an investigator-initiated, multicenter, observational trial currently underway in 4 centers in Spain (Hospital Clínico San Carlos, Hospital Universitario La Paz, Hospital General Universitario de Ciudad Real, and Hospital Universitario Gregorio Marañón), and open to more participant hospitals. Only tertiary care hospitals with extensive expertise in the management of SCD and post-resuscitation care will participate in the trial. All of them are required to have on-site 24 hours a day, 7 days a week availability for percutaneous coronary intervention, and critical care units staffed by cardiologists and/or critical care specialists. This selective center recruitment is supported by recent data suggesting that direct admission to invasive heart centers is associated with lower mortality in patients with out-of-hospital cardiac arrest (OHCA).

Consecutive patients admitted to the hospital after out or in-hospital cardiac arrest due to VF will be registered and screened for potential inclusion in the study. Patients will be classified into either of two groups:

1. Study group: comatose survivors (GCS ≤8) after RoSC and, in whom neurological prognosis is unknown at the time of admission. This group is divided into a prospective cohort (new admissions), and a retrospective one, in which cases will be obtained from existing databases in the participating centers.
2. Control group: patients who are conscious (GCS=15) and whose neurological status is known and good at admission. This will be the control group for the spectral-based predictive model, setting the gold standard for predicting FNP.

Ethics:

The study protocol has been approved by the ethics committee of the Hospital Clínico San Carlos, which in is in accordance with the Helsinki Declaration. Every patient will be requested to sign the informed consent before inclusion in the trial. If patient's condition makes it unfeasible to obtain a signed informed consent, it will be requested to their next of kin. Prospective patients will be requested to sign the informed consent during hospital admission, whereas retrospective patients/relatives will sign the informed consent at the time of follow-up contact. The main investigator at each participating center will be responsible for its on-site obtainment and storage according to current Spanish law.

Decisions to withdraw advanced life support will be led by the physician in charge and discussed with representatives according to institutional standards, with no intervention whatsoever from the investigating team.

Eligible patients will need to fulfill all of the inclusion criteria. Exclusion criteria will also apply.

Temperature management in comatose survivors after cardiac arrest due to ventricular fibrillation:

Patients included in the study group must have undergone therapeutic mild hypothermia (target temperature 32 to 34ºC) or controlled normothermia (target temperature 36ºC) for at least 24 hours according to the institution protocol, as long the it is in agreement with current requirements. Routine use of prehospital or in-hospital cooling during cardiopulmonary resuscitation with rapid infusion of large volumes of cold intravenous fluid is discouraged, due to lack of evidence to improve neurological outcome or mortality. Rewarming strategies (e.g. passive or active rewarming) are open depending on institutional standards. Sedation, drug-induced paralysis during mechanical ventilation, the use of cardiovascular drugs, support devices or any other intensive care therapy is left at the criteria of the treating physicians.

Data collection and spectral analysis of VF tracings:

All data, either from the prospective or the retrospective cohort, will be entered in an electronic Case Report Form (eCRF) by individual investigators at each center. Demographic and clinical variables will be obtained from all available medical records and by in-person interview, if possible. Clinical variables and biomarkers as neuron-specific enolase (highest recorded value), electroencephalogram, somatosensory evoked potentials (N20 component with median nerve stimulation) and brain imaging, are encouraging to be collected in the prospective cohort, if available. VF recordings prior to the first DC shock will be scanned using commercial desktop scanners (600 dots per inch) and uploaded to the eCRF. Data consistency and quality will be weekly monitored by one of the investigators (M.M.B).

Stored ECG traces in a codified digital format will be processed as reported elsewhere. Briefly, digitization will be performed using a supervised semi-automatic approach based on region of interest selection, histogram thresholding and intensity transformations. Up to 5-s long segments are extracted after segmentation and signal codification from artifact-free VF tracings. Signals are band-pass filtered between 1.5 and 40 Hz. Two independent investigators will visually inspect the extraction quality (J.G.Q and M.M.B). Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency (DF), the relative power between high and low frequency bands (cut-off: 3.9 Hz) (HL-PSDR), and the relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power (rHL-pKR), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction. Investigators blinded to clinical outcome will perform all data analysis, extraction and quantification using custom-made scripts of MATLAB software (V. 2016b, The Mathworks). The results of such analysis will not be disclosed to the treating physicians and site investigators, not to interfere in standard care, decision-making and outcome assessment.

Outcome assessment:

The primary clinical outcome will be FNP during hospitalization. All patients will be classified using the Pittsburgh Cerebral Performance Categories (CPC) outcome categorization of brain injury, according to current standards of care for SCD assessment. Patients will be considered to have FNP if they score 1 or 2 in the CPC scale (good performance and moderate disability, respectively). CPCs 3, 4 and 5 (severe disability, vegetative state and brain death, respectively) will be considered as a non-FNP. In the prospective cohort, neurological outcome will also be determined using the mini-mental state examination (MMSE). The threshold value in MMSE for normal cognitive function is 24/30, which will be used as complementary neurological evaluation.

In the prospective cohort, neurological outcome will be established before hospital discharge. In the retrospective cohort, the assessment will be done using medical records and in-person interviews with the patient or relatives. During follow-up, neurological outcome will be prospectively assessed by in-person interview in all survivors. Patients within the prospective cohort will be evaluated 6 months after hospitalization. In the retrospective cohort, the follow-up will take place at the moment of patient enrolment or contact with patient´s relatives, in case of decease.

The secondary clinical outcomes will be survival to hospital discharge, and FNP and survival at follow-up. The control group will be used to test the predictive model against a cohort of patients with known FNP, in which the model should also properly predict FNP.

Sample size and study timeline:

The sample size was estimated using the diagnostic performance obtained from the pivotal study. The spectral-based four-variable model using DF, HL-PkR , HL-PSDR, and the number of shocks delivered before ROSC, showed a diagnostic sensitivity of 0.94. Looking for a 95% confidence interval and 5% precision, and assuming that 61% patients will show FNP according to our previous research, a total 143 individuals (both prospective and retrospective cohorts) suitable for analysis must be included.

It is estimated that each of the aforementioned centers receives ~60 SCD per year, but only around one fourth of them will fulfill the inclusion criteria, namely VF as first documented rhythm and ECG tracing availability. Considering the inclusion of 2 more centers (currently undertaking protocol evaluation), the incidence of annual new cases per hospital and retrospective cases from previous years, the sample size will be achieved in a time frame of 30 months. The latter includes the follow-up period for the last group of patients who will be enrolled in the study. As of the writing of this manuscript, the starting center (Hospital Clínico San Carlos) has already evaluated 60 patients, of who 21 met the inclusion criteria and are enrolled in the trial.

Statistical analysis:

Patients from the study group (prospective and retrospective) will be categorized according to the risk score obtained from the multivariate spectral-based model. More specifically, patients will be categorized within four subsets for FNP as follows: very high and high probability of FNP (expected FNP), low and very low probability of FNP (expected non-FNP). Model-derived categorization will be compared with clinical outcomes to assess model sensitivity, specificity and accuracy during hospitalization and follow-up.

In order to assess the clinical relevance of the spectral-based model the investigators will compare its performance and overall accuracy with a model built using the most associated and clinically relevant variables (e.g. highest recorded value of neuron-specific enolase, somatosensory evoked potentials) to the primary outcome. To develop a clinical-based predictive model, each of the clinical variables will undergo univariate analysis to evaluate its association with in-hospital FNP.

Normal distribution of variables will be assessed with the Shapiro-Wilk test. Statistical significance will be assessed by the parametric Student's t-test or the non-parametric Mann-Whitney test, as appropriate. If necessary, the investigators will use Bonferroni correction for multiple comparisons. Categorical variables and percentile comparisons will be performed using a Chi-squared test or the Fisher's exact test, as appropriate. Two-sided p<0.05 will be considered statistically significant. Variables with statistically significant differences and clinically relevant variables will be regressed out against the in-hospital FNP by using a stepwise backwards multivariate logistic regression approach. The clinical-based model will be developed to predict FNP with the highest sensitivity and specificity achievable by using the minimum number of variables that guarantees the best performance and predictive accuracy.

Study Design

• Study Type: Observational
• Estimated Enrollment: 143 participants
• Observational Model: Cohort
• Time Perspective: Other
• Official Title: Early Prognostic Value of an Algorithm Based on Spectral Variables of Ventricular fibrillAtion From the EKG of Patients With suddEn Cardiac Death: a Multicenter Observational Trial
• Study Start Date: June 2016
• Estimated Primary Completion Date: June 2021
• Estimated Study Completion Date: December 2021

Groups and Cohorts

Group/Cohort	Intervention/treatment
Study; Comatose survivors (GCS ≤8) after RoSC, in whom neurological prognosis is unknown at the time of admission. Neurological performance of patients from the study group (prospective and retrospective) will be categorized according to a risk score obtained from the multivariate spectral-based model.	Diagnostic Test: Spectral analysis of ventricular fibrillation tracings; Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
Control; Patients who are conscious (GCS=15) and whose neurological status is known and good at admission.	Diagnostic Test: Spectral analysis of ventricular fibrillation tracings; Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.

Outcome Measures

Primary Outcome Measures :

1. Favorable neurological performance (FNP) during hospitalization [ Time Frame: Hospitalization, up to 2 months after admission ]

   Patients will be assessed using the Pittsburgh Cerebral Performance Categories (CPC) outcome categorization of brain injury. They will be considered to have FNP if they score 1 or 2 in the CPC scale (good performance and moderate disability, respectively). CPCs 3, 4 and 5 (severe disability, vegetative state and brain death, respectively) will be considered as a non-FNP.

   In the prospective cohort, FNP will also be determined using the mini-mental state examination (cut-off value 24/30).

Secondary Outcome Measures :

1. Survival to hospital discharge [ Time Frame: Hospitalization, up to 2 months ]
   Patients discharged alive
2. Favorable neurological performance (FNP) at follow-up [ Time Frame: 6 months after discharge (prospective patients) or at patient enrollment (retrospective patients) ]
   Patients will be assessed using the Pittsburgh Cerebral Performance Categories (CPC) outcome categorization of brain injury. They will be considered to have FNP if they score 1 or 2 in the CPC scale (good performance and moderate disability, respectively). CPCs 3, 4 and 5 (severe disability, vegetative state and brain death, respectively) will be considered as a non-FNP.
3. Survival at follow-up [ Time Frame: 6 months after discharge (prospective patients) or at patient enrollment (retrospective patients) ]
   Patients alive at the time of follow-up

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Consecutive patients admitted to the hospital after out or in-hospital cardiac arrest due to VF will be registered and screened for potential inclusion in the study. Patients will be classified into either of two groups:

1. Study group: comatose survivors (GCS ≤8) after RoSC, in whom neurological prognosis is unknown at the time of admission. This group is divided into a prospective cohort (new admissions), and a retrospective one, in which cases will be obtained from existing databases in the participating centers.
2. Control group: patients who are conscious (GCS=15) and whose neurological status is known and good at admission. This will be the control group for the spectral-based predictive model (gold standard for FNP).

Criteria

Inclusion Criteria:

• In or out-of-hospital cardiac arrest with ventricular fibrillation (VF) as first documented rhythm.
• A ≥3-second VF tracings before the first direct current (DC) shock.
• Signed informed consent. Patients unable to consent, it will be requested to an authorized relative.
• Study group: GCS ≤8 and subject to temperature management (hypothermia 32-34ºC or normothermia 36ºC).
• Control group: GCS=15, thus no indication for temperature management.

Exclusion Criteria:

• First documented rhythm other than VF (e.g. ventricular tachycardia, pulseless electrical activity, asystole)
• Unavailable or suboptimal quality of the ECG tracing before the first DC shock.
• Terminal disease or cognitive impairment before the SCD event.
• Other possible causes of comatose status different from SCD (e.g. drugs, traumatic brain injury, hypoxia).
• Aged under 18 .
• Unwilling to provide the informed consent.
• Comatose status (GCS≤8) and absence of temperature management or GCS ≥9 if temperature management was undertaken.
• Hemodynamic instability leading to incomplete 24 h of temperature management
• Early mortality and absence of subsequent withdrawal of sedation to assess cerebral performance.

Contacts and Locations

Contacts

Contact: David Filgueiras-Rama, MD; +913303696; david.filgueiras@cnic.es

Contact: Julián Palacios-Rubio, MD; +913307045; palaciosrubioj@gmail.com

Locations

Spain

Hospital General Universitario de Ciudad Real; Recruiting

Ciudad Real, Spain, 13005

Contact: Carmen Corcobado-Márquez, MD +34926278000 ext 78753 mccorcobado@hotmail.com

Principal Investigator: Carmen Corcobado-Márquez, MD

Sub-Investigator: Francisco Ruiz-Lorenzo, MD

Sub-Investigator: Carmen Espinosa-González, MD

Hospital General Universitario Gregorio Marañón; Active, not recruiting

Madrid, Spain, 28007

Fundación Centro Nacional de Investigaciones Cardiovasculares, Carlos III; Active, not recruiting

Madrid, Spain, 28029

Hospital Clínico San Carlos; Recruiting

Madrid, Spain, 28040

Contact: David Filgueiras-Rama, MD +34913303696 david.filgueiras@cnic.es

Contact: Julián Palacios-Rubio, MD +34913307045 julian.palacios@salud.madrid.org

Principal Investigator: Julián Palacios-Rubio, MD

Sub-Investigator: Inés García-González, MD

Sub-Investigator: José M. Gil-Perdomo, MD

Sub-Investigator: María Bringas-Bollada, MD

Hospital Universitario La Paz; Recruiting

Madrid, Spain, 28046

Contact: Esteban López de Sa, MD +34917277000 estebanlopezdesa@secardiologia.es

Principal Investigator: Esteban López de Sa, MD

Sub-Investigator: Verónica Rial-Bastón, MD

Sponsors and Collaborators

Hospital San Carlos, Madrid

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Hospital Universitario La Paz

Hospital General de Ciudad Real

Fundación de Investigación en Red en Enfermedades Cardiovasculares

Hospital General Universitario Gregorio Marañon

Sociedad Española de Cardiología

Fundacion Investigacion Interhospitalaria Cardiovascular

Investigators

• Principal Investigator: David Filgueiras-Rama, MD; Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
• Study Chair: Manuel Marina-Breysse, MD; Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
• Study Chair: María-Jesús García-Torrent, PharmD, PhD; Hospital Clínico San Carlos

More Information

Publications of Results:

Filgueiras-Rama D, Calvo CJ, Salvador-Montañés Ó, Cádenas R, Ruiz-Cantador J, Armada E, Rey JR, Merino JL, Peinado R, Pérez-Castellano N, Pérez-Villacastín J, Quintanilla JG, Jiménez S, Castells F, Chorro FJ, López-Sendón JL, Berenfeld O, Jalife J, López de Sá E, Millet J. Spectral analysis-based risk score enables early prediction of mortality and cerebral performance in patients undergoing therapeutic hypothermia for ventricular fibrillation and comatose status. Int J Cardiol. 2015;186:250-8. doi: 10.1016/j.ijcard.2015.03.074. Epub 2015 Mar 14.

Other Publications:

Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ; ESC Scientific Document Group . 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov 1;36(41):2793-2867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Palacios-Rubio J, Marina-Breysse M, Quintanilla JG, Gil-Perdomo JM, Juárez-Fernández M, Garcia-Gonzalez I, Rial-Bastón V, Corcobado MC, Espinosa MC, Ruiz F, Gómez-Mascaraque Pérez F, Bringas-Bollada M, Lillo-Castellano JM, Pérez-Castellano N, Martínez-Sellés M, López de Sá E, Martín-Benítez JC, Perez-Villacastín J, Filgueiras-Rama D. Early prognostic value of an Algorithm based on spectral Variables of Ventricular fibrillAtion from the EKG of patients with suddEn cardiac death: A multicentre observational study (AWAKE). Arch Cardiol Mex. 2018 Dec;88(5):460-467. doi: 10.1016/j.acmx.2018.05.003. Epub 2018 Jun 7.

• Responsible Party: David Filgueiras-Rama, MD, PhD, Hospital San Carlos, Madrid
• ClinicalTrials.gov Identifier: NCT03248557
• Other Study ID Numbers: 16/405-E
• First Posted: August 14, 2017
• Last Update Posted: February 16, 2021
• Last Verified: February 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by David Filgueiras-Rama, Hospital San Carlos, Madrid:

resuscitation; wavelet analysis; spectral analysis; post-cardiac arrest syndrome

Additional relevant MeSH terms:

Reperfusion Injury; Death, Sudden, Cardiac; Ventricular Fibrillation; Death; Pathologic Processes; Vascular Diseases; Cardiovascular Diseases; Postoperative Complications; Heart Arrest; Heart Diseases; Death, Sudden; Arrhythmias, Cardiac